K
Krister Kristiansson
Researcher at Merck & Co.
Publications - 3
Citations - 6942
Krister Kristiansson is an academic researcher from Merck & Co.. The author has contributed to research in topics: Losartan & Left ventricular hypertrophy. The author has an hindex of 3, co-authored 3 publications receiving 6805 citations.
Papers
More filters
Journal ArticleDOI
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
TL;DR: Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.
Journal ArticleDOI
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lars H Lindholm,Hans Ibsen,Björn Dahlöf,Richard B. Devereux,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Stevo Julius,Sverre E. Kjeldsen,Krister Kristiansson,Ole Lederballe-Pedersen,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel,Peter Aurup,Jonathan M. Edelman,Steven M. Snapinn +17 more
TL;DR: Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH.
Journal ArticleDOI
812-4 Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension (LIFE) study
Jorge R. Kizer,Aud Høieggen,Michael H. Alderman,Sverre E. Kjeldsen,Björn Dahlöf,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Marku S Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel,Jonathan M. Edelman,Steven M. Snapinn,Richard B. Devereux +19 more
TL;DR: Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: the losartan intervention for endpoint reduction in hypertension.